ANALYSIS OF CLINICAL EFFICACY AND SAFETY OF INTRAVENOUS USE OF DICLOFENAC FOR THE PREVENTION OF POSTOPERATIVE PAIN: CURRENT STATUS AND STRATEGIC ASPECT

E. Litvinova

**1. Introduction**

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of drugs that are widely used in clinical practice. More than thirty million people worldwide receive NSAIDs daily, with 40% of those patients over 60 years of age. About 20% of inpatients receive NSAIDs. Their popularity is explained by the fact that they have anti-inflammatory, analgesic and antipyretic effects and provide relief to patients with relevant symptoms (inflammation, pain, fever), which are noted in many diseases [1].

The favorable efficacy / safety ratio, as evidenced in numerous adequate clinical studies, makes it possible to consider NSAIDs – diclofenac as the drug of choice for the treatment of degenerative-dystrophic diseases of the musculoskeletal system and other conditions accompanied by pain of different localization and intensity. Diclofenac sodium was first synthesized in 1964 and since 1974 has been widely used by doctors around the world. Using a production diversification strategy, diclofenac dosage forms for topical application, tablet formulations, injection forms were developed to improve the efficacy, tolerability and convenience of the patient [2].

In the general structure of drug therapy, postoperative pain, NSAIDs are analgesics, which are the most commonly prescribed worldwide. WHO recommends the designation of NSAIDs as the first step in postoperative analgesia. According to the Practical Guide to the Treatment of Postoperative Pain (American Society for Pain Management, 2016), NSAIDs are the most important components in a system of multimodal analgesia. Their use, as a component of multimodal anesthesia, reduces the need for opioids and, accordingly, the frequency of postoperative nausea and vomiting, reduce the degree of sedation, provide early mobilization [3].

In intense acute pain (surgery), the speed of pain relief can be of fundamental importance. In this case, intravenous use of NSAIDs is justified [4, 5]. However, the benefit of such administration is maintained only during the first day of treatment.

In the short term after surgery, for the pain relief purpose NSAIDs are often prescribed, along with opioids (such as morphine). However, NSAIDs can cause bleeding (such as in the incision or wound) and lead to damage to the kidneys and intestines [6, 7]. Evidence is available
that intravenous diclofenac is effective in reducing pain after surgery in adults, but it is not fully known how safe it is to use in these conditions.

The aim of the work is the analysis and systematization of literature data on the current state and strategic aspect of intravenous use of diclofenac for the prevention of postoperative pain, namely clinical efficacy and safety.

2. Planning (methodology) of research

The following research plan has been developed:
- comparative analysis of diclofenac sodium dosage forms for injections which were registered at the Food and Drug Administration, European Medicines Agency, as well as are presented in the British National Formulary;
- comparative analysis of controlled clinical studies of the efficacy and safety of various injectable forms of diclofenac sodium;
- analysis of data from more than one study, including any integrated analyzes, meta-analyses, comparative analyzes of studies;
- determination of perspectives of practical medical application of systematic results and directions of further research on the topic.

3. Materials and methods

Studies were conducted using databases on the Internet: PubMed; Food and Drug Administration, European Medicines Agency. It has used retrospective, logical, research methods, content analysis.

Injectable preparations containing diclofenac sodium 75 mg, propylene glycol and benzyl alcohol, have been available in the UK since 1997 and are widely used in many countries [2]. The intravenous administration of this injectable form of diclofenac sodium is not indicated in the instructions for use in all European countries, according to the European Medicines Agency. But, diclofenac, solution for injection, 75 mg/3 ml (for intravenous infusion), registered in countries (Austria, Belgium, Bulgaria, Czech Republic, Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Malta, Portugal, Romania, Slovakia, Sweden, the Netherlands, and the United Kingdom) with strict regulatory authorities. It should be noted that the drug Voltarol, solution for injection (Novartis Pharmaceuticals UK Ltd) for the prevention of postoperative pain in the form of intravenous infusions is presented in the British National Formulary (2018–2019), containing the main provisions of the system to ensure effective and safe pharmacotherapy [8]. However, these drugs require a long infusion time when administered intravenously. A new Dyloject injectable drug, Hospira Inc., USA, has been approved in the United States for 37.5 mg sodium diclofenac and includes hydroxypropyl-β-cyclodextrin for increased solubility with pH modifiers and monothioglycerin [9]. Unlike the known diclofenac sodium injectables, Dyloject does not produce propylene glycol, and improved solubility is achieved by the hydroxypropyl-β-cyclodextrin excipient, which also shortens the time of intravenous administration.

4. Results of the research

Table 1 presents the results of the analysis and systematization of the clinical efficacy and tolerability of the use of diclofenac to prevent postoperative pain with intravenous administration.

<table>
<thead>
<tr>
<th>No.</th>
<th>Research</th>
<th>Efficacy and tolerability of diclofenac</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Retrospective, total hip arthroplasty [10]</td>
<td>Adjunctive intravenous administration of diclofenac reduces opioid consumption and increases satisfaction in primary total hip arthroplasty</td>
</tr>
<tr>
<td>2</td>
<td>2 double-blind, randomized, placebo-controlled, surgical orthopedics (n=608) [11]</td>
<td>Injectable hydroxypropyl-β-cyclodextrin-diclofenac reduced the need for postoperative opioids after abdominal / pelvic or orthopedic surgery</td>
</tr>
<tr>
<td>3</td>
<td>Multicenter, randomized, double, blind, surgical orthopedics (n=277) [12]</td>
<td>Hydroxypropyl-β-cyclodextrin-diclofenac is safe and effective in acute moderate and severe pain after orthopedic surgery, significantly reducing the use of morphine</td>
</tr>
<tr>
<td>4</td>
<td>Pilot, cholecystectomy (n=50) [13]</td>
<td>It has established effectiveness of intravenous diclofenac for laparoscopic pain after cholecystectomy</td>
</tr>
<tr>
<td>5</td>
<td>Randomized, surgical oncology procedures (n=70) [14]</td>
<td>Intravenous infusion of diclofenac is considered as a safe alternative to infusion of tramadol for the treatment of pain after extensive surgical oncology procedures</td>
</tr>
<tr>
<td>6</td>
<td>Pilot, obstetrics and gynecology (n=100) [15]</td>
<td>It has established efficacy in reducing pain by intravenous paracetamol and intravenous diclofenac administration, relative safety</td>
</tr>
<tr>
<td>7</td>
<td>Prospective, double-blind, randomized, surgical procedure (n=120) [16]</td>
<td>Both paracetamol and diclofenac preparations provided analgesia for intravenous postoperative administration without any significant side effects</td>
</tr>
<tr>
<td>8</td>
<td>Double-blind, randomized, placebo-controlled, hip and knee replacement (n=102) [17]</td>
<td>Preoperative intravenous administration of diclofenac 75 mg or ketorolac 60 mg significantly reduces the need for morphine and associated side effects after major orthopedic surgery</td>
</tr>
<tr>
<td>9</td>
<td>Randomized, double-blind, placebo-controlled, knee arthroplasty (n=64) [18]</td>
<td>In the first day after arthroplasty of the knee joint diclofenac and ketoprofen had an opioid-saving effect</td>
</tr>
</tbody>
</table>
5. Discussion of the results

The supplied results indicate that diclofenac sodium when administered intravenously is effective and safe in patients experiencing acute postoperative pain, or as part of a multimodal analgesic strategy to achieve perioperative pain control.

Along with a wide range of pharmacological action, high therapeutic efficacy, a number of side effects of diclofenac with intravenous administration should be noted.

The results of the Cochrane review (2018) of 8 studies involving 1756 people in whom diclofenac was administered intravenously to relieve pain after surgery in adults indicate that diclofenac is more effective than placebo and similar to other NSAIDs. Studies did not provide sufficient information on adequate assessment of side effects, but their incidence was similar to that seen with other treatments [25].

A safety analysis of 7 single-dose clinical trials was performed involving 531 patients who received either a rapid intravenous Dyloject bolus or a 30-minute intravenous infusion of Voltarol containing diclofenac sodium, propylene glycol and benzyl alcohol. The incidence of thrombophlebitis, observed, as an undesirable phenomenon after Dyloject treatment, was 1.2% (5 of 423) compared to 6.5% (7 of 108) after Voltarol [26].

In the study of the pharmacokinetics of intravenous Dyloject compared with Voltarol, no serious side effects were observed [27]. No clinically relevant changes in clinical laboratory tests, ECGs or indicators of vital function were found.

Dyloject has been investigated for the treatment of moderate-to-severe postoperative pain in 1289 patients ≥ 65 years of age. The overall incidence of adverse events in patients aged 65-74 or ≥ 75 years was similar to patients aged <65 years [28].

Studies by other authors also confirm the good tolerability of the 75 mg/1 ml diclofenac sodium solution, which was administered intravenously [29].

Post-operative use of Dyloject has been reported to pose no additional risk for cardiovascular safety compared to placebo [30].

Although numerous placebo-controlled studies of diclofenac, a solution for injection, are important evidence of its efficacy and tolerability, there is a higher degree of evidence of its clinical benefits. A widely recognized standard for evidence-based medicine is multicenter research data.

In a prospective, randomized multicenter trial, the risk of death, increased bleeding at the site of surgery, gastrointestinal bleeding, acute renal failure, and allergic reactions, with parenteral and oral administration of ketorolacene or diclofenac compared to diclopropolac was evaluated. Patients were observed within 30 days after surgery. A total of 11,245 patients were screened in 49 European hospitals. The overall risk of serious side effects with the use of diclofenac and NSAIDs in the study was very low.

Conducted clinical data analysis indicates that diclofenac sodium, when administered intravenously, has an opioid-saving effect, is effective in patients experiencing acute postoperative pain, or as part of a multimodal analgesic strategy to achieve perioperative pain control.

Limitations of research. A limitation of the study is the small sample size (<100 patients) of some previously conducted clinical studies of the efficacy and safety of injectable forms of diclofenac sodium.

Prospects for further development of this field. It is promising to create domestic diclofenac sodium preparations for intravenous administration, which have improved solubility, and to conduct large-scale population studies to determine the risks of serious side effects associated with intravenous diclofenac compared with other injections.

6. Conclusions

Thus, the experience of clinical intravenous use of diclofenac sodium for the prevention of postoperative pain has confirmed its efficacy, favorable safety profile and the ability to reduce the need for opiates. The promising strategic aspect is the creation of domestic diclofenac sodium preparations for intravenous administration, which have improved solubility, shorter administration time than infusions and have no additional safety risk.


Received date 04.12.2019
Accepted date 12.02.2020
Published date 29.02.2020

Elena Litvinova, Doctor of Pharmaceutical Sciences, Associate Professor, Department of Management and Economics of Enterprise, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: hlitvinova@gmail.com